Ticagrelor: Pharmacokinetics, pharmacodynamics, clinical efficacy, and safety

Paul P. Dobesh, Julie H. Oestreich

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Dual antiplatelet therapy, composed of aspirin plus a P2Y12-receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of U.S. Food and Drug Administration-approved P2Y12-receptor antagonists are available for treating patients with ACS, including the thienopyridine compounds clopidogrel and prasugrel. Ticagrelor, the first of a new class of antiplatelet agents, is a noncompetitive, direct-acting P2Y12-receptor antagonist. Unlike the thienopyridine compounds, ticagrelor does not require metabolism for activity. Also, whereas clopidogrel and prasugrel are irreversible inhibitors of the P2Y12 receptor, ticagrelor binds reversibly to inhibit receptor signaling and subsequent platelet activation. In pharmacodynamic studies, ticagrelor demonstrated faster onset and more potent inhibition of platelet aggregation than clopidogrel. These properties of ticagrelor may contribute to reduced rates of thrombotic outcomes compared with clopidogrel, as demonstrated in a phase III clinical trial. However, in addition to bleeding, distinctive adverse effects of this new chemical entity have not been reported with the thienopyridine P2Y12-receptor inhibitors. Although ticagrelor represents an advancement in P2Y12-receptor inhibition therapy, a thorough understanding of this compound as an antiplatelet therapy remains to be elucidated.

Original languageEnglish (US)
Pages (from-to)1077-1090
Number of pages14
JournalPharmacotherapy
Volume34
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

clopidogrel
Purinergic P2Y Receptor Antagonists
Pharmacokinetics
Safety
Acute Coronary Syndrome
Phase III Clinical Trials
Platelet Aggregation Inhibitors
Platelet Activation
United States Food and Drug Administration
Therapeutics
Platelet Aggregation
Aspirin
Ticagrelor
Hemorrhage

Keywords

  • ACS
  • CAD
  • P2Y inhibitors
  • acute coronary syndrome
  • antiplatelets
  • coronary artery disease
  • ticagrelor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ticagrelor : Pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. / Dobesh, Paul P.; Oestreich, Julie H.

In: Pharmacotherapy, Vol. 34, No. 10, 01.10.2014, p. 1077-1090.

Research output: Contribution to journalArticle

@article{f6fae11b89474664969f11b1044d42f2,
title = "Ticagrelor: Pharmacokinetics, pharmacodynamics, clinical efficacy, and safety",
abstract = "Dual antiplatelet therapy, composed of aspirin plus a P2Y12-receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of U.S. Food and Drug Administration-approved P2Y12-receptor antagonists are available for treating patients with ACS, including the thienopyridine compounds clopidogrel and prasugrel. Ticagrelor, the first of a new class of antiplatelet agents, is a noncompetitive, direct-acting P2Y12-receptor antagonist. Unlike the thienopyridine compounds, ticagrelor does not require metabolism for activity. Also, whereas clopidogrel and prasugrel are irreversible inhibitors of the P2Y12 receptor, ticagrelor binds reversibly to inhibit receptor signaling and subsequent platelet activation. In pharmacodynamic studies, ticagrelor demonstrated faster onset and more potent inhibition of platelet aggregation than clopidogrel. These properties of ticagrelor may contribute to reduced rates of thrombotic outcomes compared with clopidogrel, as demonstrated in a phase III clinical trial. However, in addition to bleeding, distinctive adverse effects of this new chemical entity have not been reported with the thienopyridine P2Y12-receptor inhibitors. Although ticagrelor represents an advancement in P2Y12-receptor inhibition therapy, a thorough understanding of this compound as an antiplatelet therapy remains to be elucidated.",
keywords = "ACS, CAD, P2Y inhibitors, acute coronary syndrome, antiplatelets, coronary artery disease, ticagrelor",
author = "Dobesh, {Paul P.} and Oestreich, {Julie H.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1002/phar.1477",
language = "English (US)",
volume = "34",
pages = "1077--1090",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Ticagrelor

T2 - Pharmacokinetics, pharmacodynamics, clinical efficacy, and safety

AU - Dobesh, Paul P.

AU - Oestreich, Julie H.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Dual antiplatelet therapy, composed of aspirin plus a P2Y12-receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of U.S. Food and Drug Administration-approved P2Y12-receptor antagonists are available for treating patients with ACS, including the thienopyridine compounds clopidogrel and prasugrel. Ticagrelor, the first of a new class of antiplatelet agents, is a noncompetitive, direct-acting P2Y12-receptor antagonist. Unlike the thienopyridine compounds, ticagrelor does not require metabolism for activity. Also, whereas clopidogrel and prasugrel are irreversible inhibitors of the P2Y12 receptor, ticagrelor binds reversibly to inhibit receptor signaling and subsequent platelet activation. In pharmacodynamic studies, ticagrelor demonstrated faster onset and more potent inhibition of platelet aggregation than clopidogrel. These properties of ticagrelor may contribute to reduced rates of thrombotic outcomes compared with clopidogrel, as demonstrated in a phase III clinical trial. However, in addition to bleeding, distinctive adverse effects of this new chemical entity have not been reported with the thienopyridine P2Y12-receptor inhibitors. Although ticagrelor represents an advancement in P2Y12-receptor inhibition therapy, a thorough understanding of this compound as an antiplatelet therapy remains to be elucidated.

AB - Dual antiplatelet therapy, composed of aspirin plus a P2Y12-receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of U.S. Food and Drug Administration-approved P2Y12-receptor antagonists are available for treating patients with ACS, including the thienopyridine compounds clopidogrel and prasugrel. Ticagrelor, the first of a new class of antiplatelet agents, is a noncompetitive, direct-acting P2Y12-receptor antagonist. Unlike the thienopyridine compounds, ticagrelor does not require metabolism for activity. Also, whereas clopidogrel and prasugrel are irreversible inhibitors of the P2Y12 receptor, ticagrelor binds reversibly to inhibit receptor signaling and subsequent platelet activation. In pharmacodynamic studies, ticagrelor demonstrated faster onset and more potent inhibition of platelet aggregation than clopidogrel. These properties of ticagrelor may contribute to reduced rates of thrombotic outcomes compared with clopidogrel, as demonstrated in a phase III clinical trial. However, in addition to bleeding, distinctive adverse effects of this new chemical entity have not been reported with the thienopyridine P2Y12-receptor inhibitors. Although ticagrelor represents an advancement in P2Y12-receptor inhibition therapy, a thorough understanding of this compound as an antiplatelet therapy remains to be elucidated.

KW - ACS

KW - CAD

KW - P2Y inhibitors

KW - acute coronary syndrome

KW - antiplatelets

KW - coronary artery disease

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84908204751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908204751&partnerID=8YFLogxK

U2 - 10.1002/phar.1477

DO - 10.1002/phar.1477

M3 - Article

C2 - 25164528

AN - SCOPUS:84908204751

VL - 34

SP - 1077

EP - 1090

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10

ER -